ScandiBio
Stockholm, SE · 1 known investors
ScandiBio Therapeutics is a Stockholm-based pharmaceutical company developing AI-discovered drugs that target mitochondrial dysfunction to treat neurodegenerative and metabolic diseases. Its lead product, a Combined Metabolic Activator (CMA), is in a Phase III clinical trial in Turkey for patients with Alzheimer's disease.
Founders & leadership
ON
Olof NordCEO
Investors · 1
Frequently asked questions
- What does ScandiBio do?
- ScandiBio Therapeutics is a Stockholm-based pharmaceutical company developing AI-discovered drugs that target mitochondrial dysfunction to treat neurodegenerative and metabolic diseases. Its lead product, a Combined Metabolic Activator (CMA), is in a Phase III clinical trial in Turkey for patients with Alzheimer's disease.
- Who are ScandiBio's investors?
- ScandiBio's investors include Navigare Ventures.
- Where is ScandiBio headquartered?
- ScandiBio is headquartered in Stockholm, SE.